Please login to the form below

Not currently logged in
Email:
Password:

licenses

This page shows the latest licenses news and features for those working in and with pharma, biotech and healthcare.

Sanofi’s PD-1 inhibitor starts EU review for skin cancer

Sanofi’s PD-1 inhibitor starts EU review for skin cancer

It is in the first stage in a rolling license application for the drug, which is already underway in the US.

Latest news

More from news
Approximately 1 fully matching, plus 433 partially matching documents found.

Latest Intelligence

  • Licensing

    Healthcare terms - Licensing.

  • Pharma deals continue to slide Pharma deals continue to slide

    This month, both AstraZeneca and Lilly have entered into technology platform discovery deals with an option to license. ... It is also good to see big pharma continuing to license out projects that are no longer of interest.

  • Deal Watch - May 2017 Deal Watch - May 2017

    Are multiple regional deals better than a global deal? It is usual for big pharma to license global rights but in some cases regional deals are preferred either by the licensor

  • Deal Watch March 2017 Deal Watch March 2017

    Editas Medicine has entered a strategic R&D alliance where Allergan has exclusive access to Editas’s CRISPR genome-editing programmes in ocular health, as well as options to license up

  • Deal Watch January 2017 Deal Watch January 2017

    Paying up to $1.6bn the agreement covers an exclusive option to license two investigational cardiovascular products expected to reduce cardiovascular risk in patients with elevated lipoproteins.

More from intelligence
Approximately 1 fully matching, plus 44 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics